Control of viremia and prevention of AIDS following immunotherapy of SIV-infected macaques with peptide-pulsed blood
about
Can immunotherapy be useful as a "functional cure" for infection with Human Immunodeficiency Virus-1?HIV therapeutic vaccines: moving towards a functional cureTherapeutic DNA vaccine induces broad T cell responses in the gut and sustained protection from viral rebound and AIDS in SIV-infected rhesus macaquesAn "escape clock" for estimating the turnover of SIV DNA in resting CD4⁺ T cellsAIDS vaccine for Asia Network (AVAN): expanding the regional role in developing HIV vaccinesVaccine design for CD8 T lymphocyte responsesRepeated DNA therapeutic vaccination of chronically SIV-infected macaques provides additional virological benefitTiming of immune escape linked to success or failure of vaccination.Impact of MHC class I diversity on immune control of immunodeficiency virus replication.Linking pig-tailed macaque major histocompatibility complex class I haplotypes and cytotoxic T lymphocyte escape mutations in simian immunodeficiency virus infectionBroadening of the T-cell repertoire to HIV-1 Gag p24 by vaccination of HLA-A2/DR transgenic mice with overlapping peptides in the CAF05 adjuvantA randomised, placebo-controlled, first-in-human study of a novel clade C therapeutic peptide vaccine administered ex vivo to autologous white blood cells in HIV infected individuals.Defining the objectives of the AIDS vaccine for Asia network: report of the WHO-UNAIDS/Global HIV vaccine enterprise regional consultation on expanding AIDS vaccine research and development capacity in Asia.Multimodality vaccination against clade C SHIV: partial protection against mucosal challenges with a heterologous tier 2 virus.Measuring turnover of SIV DNA in resting CD4+ T cells using pyrosequencing: implications for the timing of HIV eradication therapiesSIV antigen immunization induces transient antigen-specific T cell responses and selectively activates viral replication in draining lymph nodes in retroviral suppressed rhesus macaquesHigh-avidity, high-IFNγ-producing CD8 T-cell responses following immune selection during HIV-1 infection.Circumventing antivector immunity by using adenovirus-infected blood cells for repeated application of adenovirus-vectored vaccines: proof of concept in rhesus macaques.Inactivated simian immunodeficiency virus-pulsed autologous fresh blood cells as an immunotherapy strategy.Non-immunogenicity of overlapping gag peptides pulsed on autologous cells after vaccination of HIV infected individuals.Evaluation of recombinant influenza virus-simian immunodeficiency virus vaccines in macaques.HIV epidemic in Asia: optimizing and expanding vaccine development.Epitope-specific CD8+ T cell kinetics rather than viral variability determine the timing of immune escape in simian immunodeficiency virus infection.In-vivo stimulation of macaque natural killer T cells with α-galactosylceramide.Adenovirus 5- and 35-based immunotherapy enhances the strength but not breadth or quality of immunity during chronic SIV infection.Therapeutic conserved elements (CE) DNA vaccine induces strong T-cell responses against highly conserved viral sequences during simian-human immunodeficiency virus infection.
P2860
Q26865388-A268D1AD-60BE-45A2-A3AC-594D98B0D450Q27002180-95ACE5E9-A574-41E8-A3CB-75241BA5ED66Q28481573-B3219F8A-F62F-4BF8-8B4D-0C597F997193Q28482134-666C48D0-5A98-46B8-AFD7-9337ECED6C5CQ30394227-5874D199-2F4D-4E86-A5CC-B202235B5A65Q30411492-8478D21D-444E-4310-B2F0-B75F886CB9BDQ33698152-E6ABD392-8C8C-4A18-8D2E-B66241A5115FQ33700493-D0DFA224-C7CD-4889-9B54-EC9B5870F21FQ34235198-9E201E28-6F12-40D8-A5B7-DD3A448356B9Q34595036-3F669BC9-82E7-432E-8232-33151D87C412Q34730713-AE9D245F-6F7B-4C9E-B035-062E2628036BQ34998830-1E006C60-E060-4C7D-B407-BF144AEE42B8Q35075505-14978A92-2B9C-4FCA-9E73-B3378173B52AQ35129224-DF88E7AB-CFFD-4A4A-905A-A267B18853A4Q35141776-19C80533-5516-455A-B7A5-85F070E4B39DQ35143735-B8542B27-70E3-4216-86E3-1460D90C5FA2Q35214354-E2942493-0A15-43BA-B81F-B2741A1DC241Q36276187-AE01EB4D-5BCB-4EB7-82EE-85EE788820A4Q37051629-EDA10623-0FE9-4229-8F57-816C470F94C9Q37215858-7896885E-40F0-47A1-BF88-70FF8FE6B575Q37256687-98E56E9E-C5DC-4403-AEB2-F114D2D992D0Q38036687-F5EB8A7D-D147-4E4B-9961-1934FE39904BQ41368316-77F8485C-3FB5-42DE-BBE3-99DCF6482B79Q51875279-12028AC0-DF81-4178-8311-0FA1FFE7AE3FQ51891172-5B9CFA97-457F-45FC-82A3-4CAA935BB7E1Q52592228-03E37867-ACA7-4D4D-88F8-B39605E73EAF
P2860
Control of viremia and prevention of AIDS following immunotherapy of SIV-infected macaques with peptide-pulsed blood
description
2008 nî lūn-bûn
@nan
2008 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Control of viremia and prevent ...... ques with peptide-pulsed blood
@ast
Control of viremia and prevent ...... ques with peptide-pulsed blood
@en
Control of viremia and prevent ...... ques with peptide-pulsed blood
@nl
type
label
Control of viremia and prevent ...... ques with peptide-pulsed blood
@ast
Control of viremia and prevent ...... ques with peptide-pulsed blood
@en
Control of viremia and prevent ...... ques with peptide-pulsed blood
@nl
prefLabel
Control of viremia and prevent ...... ques with peptide-pulsed blood
@ast
Control of viremia and prevent ...... ques with peptide-pulsed blood
@en
Control of viremia and prevent ...... ques with peptide-pulsed blood
@nl
P2093
P2860
P50
P1433
P1476
Control of viremia and prevent ...... ques with peptide-pulsed blood
@en
P2093
Amanda J Handley
C Jane Batten
Caroline S Fernandez
Erik Rollman
Kim Wilson
Matthew G Law
Rosemarie D Mason
Sheilajen Alcântara
Vivienne Peut
P2860
P304
P356
10.1371/JOURNAL.PPAT.1000055
P407
P577
2008-05-02T00:00:00Z